This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): StreptAvax
Description: StreptAvax vaccine is a protein-based vaccine against group A streptococcal diseases. StreptAvax is designed to induce protective immune responses to 26 different M protein serotypes of group A streptococci which are responsible for causing the vast majority of disease, including the types that are the most common causes of strep throat and invasive infections (so-called flesh-eating disease) in North America as well as the types historically associated with the most feared complication of strep throat - acute rheumatic fever. In addition, the vaccine also includes a 27th peptide derived from another protein, called Spa, which is expressed by many important pathogenic strains of streptococci.
Deal Structure: GlaxoSmithKline acquired StreptAvax through its acquisition of ID Biomedical. In September 2005, GlaxoSmithKline and ID Biomedical Corporation announced a definitive agreement for GSK to acquire ID Biomedical. In December 2005, ID Biomedical announced that the acquisition by GlaxoSmithKline closed and ID Biomedical is now a wholly-owned subsidiary of GSK.
StreptAvax vaccine News
Pink Sheet ID Biomedical StreptAvax
Pink Sheet Licensing In Brief
Additional information available to subscribers only: